Implicated in mediating therapeutic resistance in GSCs, MALAT1 confers resistance to chemotherapy, such as TMZ, and radiotherapy—standard treatments for glioblastoma (Chen et al., 2017; Kim et al., 2018). The gene discussed is MALAT1; the disease is glioblastoma.